Use of statins and risks of ovarian, uterine, and cervical diseases: a cohort study in the UK Biobank
ConclusionOur findings suggest that use of statins is associated with increased risks of cervical cancer and polycystic ovarian syndrome, but is not associated with increased or decreased risk of ovarian cancer, endometrial cancer, ovarian cyst, endometriosis, endometrial polyp, or cervical polyp. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 28, 2024 Category: Drugs & Pharmacology Source Type: research

Dose-dependent effect of lamotrigine on quetiapine serum concentration in patients using instant release tablets
ConclusionThe effect of lamotrigine in reducing quetiapine concentration is only significant for patients using quetiapine IR tablets who are treated with lamotrigine doses  >  200 mg/day. Because of high variability in the interaction effect, TDM of quetiapine should be recommended during co-prescription of high-dose lamotrigine. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 23, 2024 Category: Drugs & Pharmacology Source Type: research

Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?
ConclusionAccording to significant improvements in CAT and SGRQ score, LAMA may be preferred over LABA as a bronchodilator agent in group A COPD patients, especially in emphysema-dominant phenotype. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 23, 2024 Category: Drugs & Pharmacology Source Type: research

Dose-dependent effect of lamotrigine on quetiapine serum concentration in patients using instant release tablets
ConclusionThe effect of lamotrigine in reducing quetiapine concentration is only significant for patients using quetiapine IR tablets who are treated with lamotrigine doses  >  200 mg/day. Because of high variability in the interaction effect, TDM of quetiapine should be recommended during co-prescription of high-dose lamotrigine. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 23, 2024 Category: Drugs & Pharmacology Source Type: research

Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?
ConclusionAccording to significant improvements in CAT and SGRQ score, LAMA may be preferred over LABA as a bronchodilator agent in group A COPD patients, especially in emphysema-dominant phenotype. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 23, 2024 Category: Drugs & Pharmacology Source Type: research

DAHOS Study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome — A 3-month, multicenter, randomized controlled clinical trial
ConclusionsDapagliflozin may be an effective treatment for heart failure complicated with OSA, and could be considered as a potential new treatment for OSA. (Trial registration  www.chictr.org.cn,  ChiCTR2100049834. Registered 10 August 2021). (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 22, 2024 Category: Drugs & Pharmacology Source Type: research

Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
ConclusionEach ICI showed a unique safety profile, with certain events more frequently observed with specific ICIs, which should be considered when managing cancer patients. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 19, 2024 Category: Drugs & Pharmacology Source Type: research

A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
ConclusionsThese findings hold promise for the development of effective weight loss interventions in this population group. There is a need for more phase III studies to provide sufficient clinical evidence for the effectiveness of retatrutide, as current evidence is limited to phase II studies and has yet to prove its worth in a larger population. Here, we aimed to provide an overview of retatrutide's safety and effectiveness in treating obesity. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 17, 2024 Category: Drugs & Pharmacology Source Type: research

Effectiveness of paracetamol-NSAID combinations for upper and lower respiratory tract infections: a preliminary evaluation in primary care
(Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 17, 2024 Category: Drugs & Pharmacology Source Type: research

A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
ConclusionsThese findings hold promise for the development of effective weight loss interventions in this population group. There is a need for more phase III studies to provide sufficient clinical evidence for the effectiveness of retatrutide, as current evidence is limited to phase II studies and has yet to prove its worth in a larger population. Here, we aimed to provide an overview of retatrutide's safety and effectiveness in treating obesity. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 17, 2024 Category: Drugs & Pharmacology Source Type: research

Effectiveness of paracetamol-NSAID combinations for upper and lower respiratory tract infections: a preliminary evaluation in primary care
(Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 17, 2024 Category: Drugs & Pharmacology Source Type: research

Comparison of ticagrelor and clopidogrel in anemic patients with acute coronary syndrome: efficacy and safety outcomes over one year
ConclusionsTicagrelor and clopidogrel exhibited comparable efficacy and safety outcomes in anemic ACS patients over a one-year period. Although ticagrelor demonstrated superiority in reducing ischemic events, it is crucial to recognize the limitations of retrospective studies in informing clinical practice. This study offers valuable insights into tailoring antiplatelet therapy for anemic ACS patients and provides guidance for personalized treatment strategies, acknowledging the hypothesis-generating nature of retrospective analyses. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 16, 2024 Category: Drugs & Pharmacology Source Type: research

Exploratory associations of tacrolimus exposure and clinical outcomes after lung transplantation: A retrospective, single center experience
ConclusionA combination of Low C0/High IPV might be considered in categorizing patients towards risk of adverse clinical outcomes following lung transplantation. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 16, 2024 Category: Drugs & Pharmacology Source Type: research